Powered by MOMENTUM MEDIA
Baker & McKenzie and Clayton Utz advise on the sale of Australian-based iNova Pharmaceuticals to Canada-based Valeant Pharmaceuticals.
Firms: Baker & McKenzie (Valeant Pharmaceuticals); Clayton Utz (Ironbridge and Archer Capital)
Area: M&A
Value: $625 million upfront and up to an additional $75 million in potential milestones
Key players: The Bakers team was led by Sydney-based partner David Egan and associate Michael Dearden